We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Patents Awarded to Metabolon for Metabolomics Methods

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Patents Awarded to Metabolon for Metabolomics Methods"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Metabolon, Inc. has announced the grant of US Patent 7,682,783 and US Patent 7,682,784 entitled “Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics”.

The USPTO awarded the patents to Metabolon on March 23, 2010. The issued claims in the new patents are for uses of metabolomics to identify diagnostic biomarkers for depression and schizophrenia by profiling classes of metabolites in a sample.

The innovations provide means to identify novel metabolite biomarkers for depression or schizophrenia by profiling the biochemicals, such as sugars, nucleotides, fatty acids, amino acids and other small molecules, in patient samples and then comparing the profiles with reference profiles. These profiles and biomarkers can be developed into diagnostic tests for these mental disorders. In addition, the biomarkers can be used in drug development to monitor clinical trials.

Metabolon is the exclusive license holder of the Daouk-Kristal patent family which is comprised of early, pioneering patents and patent applications which provide fundamental IP in the field of metabolomics. The ‘783 and ’784 patents are the seventh and eighth patents to issue from the Daouk-Kristal family.